Hypoxia enhances the replication of oncolytic herpes simplex virus in p53- breast cancer cells

Cell Cycle

Volumn 8, Issue 14, 2009, Pages 2194-2197

  Fasullo, Michael ^a,b   Burch, April D ^b,c   Britton, Alicia ^a  

^a ORDWAY RESEARCH INSTITUTE   (United States)

^b STATE UNIVERSITY OF NEW YORK   (United States)

^c WADSWORTH CENTER   (United States)

Author keywords

Cancer cells; Herpes simplex virus; Hypoxia; Oncolytic therapy; p53

Indexed keywords

MITOGEN ACTIVATED PROTEIN KINASE KINASE; PROTEIN C; PROTEIN P53;

ARTICLE; BREAST CANCER; CANCER CELL CULTURE; CELL HYPOXIA; CONTROLLED STUDY; DISEASE MARKER; ENZYME ACTIVITY; GENE; HERPES SIMPLEX; HERPES SIMPLEX VIRUS 1; HUMAN; HUMAN CELL; VIRULENCE; VIRUS REPLICATION;

HUMAN HERPESVIRUS 1; SIMPLEXVIRUS;

EID: 68049110425     PISSN: 15384101     EISSN: 15514005     Source Type: Journal    
DOI: 10.4161/cc.8.14.8934     Document Type: Article

References (22)

1. Dachs GU, Greco O, Tozer GM. Targeting cancer with gene therapy using hypoxia as a stimulus. Methods Mol Med 2004; 90:371-387
2. Vaupel P. Hypoxia and aggressive tumor phenotype: implications for therapy and prognosis. Oncologist 2008; 3:21-26
3. 2 availability on human cancer. Nat Rev Cancer 2008; 8:967-975
4. Probst G, Riedinger HJ, Martin P, Engelcke M, Probst H. Fast control of DNA replication in response to hypoxia and to inhibited protein synthesis in CCRF-CEM and HeLa cells. Biol Chem 1999; 380:1371-1382 (Pubitemid 30021359)
5. Brown JM. Tumor hypoxia in cancer therapy. Methods Enzymol 2007; 435:297-321.
6. Pipiya T, Sauthoff H, Huang YQ, et al. Hypoxia reduces adenoviral replication in cancer cells by downregulation of viral protein expression. Gene Ther 2005; 12:911-917 (Pubitemid 40852209)
7. Israyelyan A, Chouljenko VN, Baghian A, David AT, Kearney MT, Kousoulas KG. Herpes simplex virus type-1(HSV-1) oncolytic and highly fusogenic mutants carrying the NV1020 genomic deletion effectively inhibit primary and metastatic tumors in mice. Virol J 2008; 5:68-77. (Pubitemid 351962614)
8. Fu X, Zhang X. Potent systemic antitumor activity from an oncolytic herpes simplex virus of syncytial phenotype. Cancer Res 2002; 62:2306-2312 (Pubitemid 34411709)
9. Chou J, Kern ER, Whitley RJ, Roizman B. Mapping of herpes simplex virus-1 neurovirulence to gamma1 34.5, a gene nonessential for growth in culture. Science 1990; 250:1262-1266
10. He B, Gross M, Roizman B. The {gamma}134.5 protein of herpes simplex virus 1 complexes with protein phosphatase 1{alpha} to dephosphorylate the alpha subunit of the eukaryotic translation initiation factor 2 and preclude the shutoff of protein synthesis by double-stranded RNA-activated protein kinase. Proc Natl Acad Sci USA 1996; 94:843-848 (Pubitemid 27074409)
11. Orvedahl A, Alexander D, Tallóczy Z, et al. HSV-1 ICP34.5 confers neurovirulence by targeting the Beclin 1 autophagy protein. Cell Host Microbe 2107; 15:23-35.
12. Harrow S, Papanastassiou V, Harland J, et al. HSV-1716 injection into the brain adjacent to tumour following surgical resection of high-grade glioma: safety data and longterm survival. Gene Ther 2004; 11:1648-1658 (Pubitemid 39530101)
13. Mace AT, Ganly I, Soutar DS, Brown SM. Potential for efficacy of the oncolytic Herpes simplex virus 1716 in patients with oral squamous cell carcinoma. Head Neck 2008; 30:1045-1051
14. Aghi MK, Liu TC, Rabkin S, Martuza RL. Hypoxia Enhances the Replication of Oncolytic Herpes Simplex Virus. Mol Ther 2008; 17:51-56
15. Hammond EM, Giaccia AJ. Hypoxia-inducible factor-1 and p53: friends, acquaintances or strangers? Clin Cancer Res 2006; 12:5007-5009
16. Bykov VJ, Issaeva N, Shilov A, Hultcrantz M, Pugacheva E, Chumakov P, et al. (2002b). Restoration of the tumor suppressor function to mutant p53 by a low-molecular-weight compound. Nat Med 2002; 8:282-288 (Pubitemid 34250107)
17. Smith K, Mezhir J, Bickenback K, et al. Activated MEK suppresses activation of PKR and enables efficient replication and in vivo oncolysis by Δγ1 34.5 mutants of herpes simplex virus I. J Virol 2006; 80:1110-1120 (Pubitemid 43134068)
18. Lester RD, Jo M, Campana WM, Gonias SL. Erythropoietin promotes MCF-7 breast cancer cell migration by an ERK/mitogen-activated protein kinase-dependent pathway and is primarily responsible for the increase in migration observed in hypoxia. J Biol Chem 2005; 280:39273-39277 (Pubitemid 41713881)
19. Burch AD, Weller SK. Nuclear sequestration of cellular chaperone and proteasomal machinery during herpes simplex virus type 1 infection. J Virol 2004; 78:7175-7185
20. Sandri-Goldin RM. The many roles of the regulatory protein ICP27 during herpes simplex virus infection. Front Biosci 2008; 13:5241-5256
21. Sansone P, Storci G, Pandolfi S, Montanaro L, Chieco P, Bonafé M. The p53 codon 72 proline allele is endowed with enhanced cell-death inducing potential in cancer cells exposed to hypoxia. Br J Cancer 2007; 96:1302-1308 (Pubitemid 46625085)
22. Pin RH, Reinblatt M, Fong Y. Employing tumor hypoxia to enhance oncolytic viral therapy in breast cancer. Surgery 2004; 136:199-210. (Pubitemid 39037654)